New radioactive tracer aims to spot colorectal cancer more clearly

NCT ID NCT07597759

Completed Diagnosis Sponsor: SmartNuclide Biopharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a radioactive tracer called 68Ga-NODAGA-SNA009 in 12 people with colorectal cancer. The tracer targets a protein (GPA33) found on cancer cells and is used with PET scans to see where the cancer is in the body. The main goals were to check safety and measure how the tracer spreads and how much radiation it delivers. This study does not test treatment, only imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-NODAGA-SNA009 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could lead to a more precise way to detect colorectal cancer using PET scans, helping doctors see tumors better.
What could go wrong: This is a very early, small study (12 people) focused on safety and imaging, not treatment. The tracer may not work well in larger groups or improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GPA33

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.